In vitro susceptibility of respiratory isolates of Aspergillus species to itraconazole and amphotericin B. Acquired resistance to itraconazole

被引:75
作者
Chryssanthou, E
机构
[1] Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institute and Hospital, Stockholm
[2] Department of Laboratory Medicine, Division of Clinical Microbiology, Karolinska Institute and Hospital
关键词
D O I
10.3109/00365549709011864
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
122 Aspergillus strains were isolated from respiratory specimens from 80 patients, Aspergillus fumigatus was the most common species, constituting 88% of the isolates, Susceptibility testing by the NCCLS broth macrodilution procedure revealed that the minimal inhibitory concentration for 50% of the strains (MIC50) was 0.25 mg/l for itraconazole and 0.5 mg/l for amphotericin B. The MIC90 was 1 mg/l for both drugs, To our knowledge, no cases of in vitro resistance during long-term itraconazole use in treatment of Aspergillus infection have been documented. We identified 3 patients infected with A. fumigatus strains that acquired in vitro resistance to itraconazole during prolonged therapy. This finding supports the importance of susceptibility testing.
引用
收藏
页码:509 / 512
页数:4
相关论文
共 24 条
  • [1] ASPERGILLOSIS
    BODEY, GP
    VARTIVARIAN, S
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1989, 8 (05) : 413 - 437
  • [2] Chronic necrotizing pulmonary aspergillosis: Pathologic outcome after itraconazole therapy
    Caras, WE
    Pluss, JL
    [J]. MAYO CLINIC PROCEEDINGS, 1996, 71 (01) : 25 - 30
  • [3] DISCREPANCIES BETWEEN MIC AND MLC VALUES OF AMPHOTERICIN-B AGAINST ISOLATES OF ASPERGILLUS SPECIES
    COLOMBO, AL
    MCGOUGH, DA
    RINALDI, MG
    [J]. MYCOPATHOLOGIA, 1994, 128 (03) : 129 - 133
  • [4] de Hoog GS, 1995, Atlas of clinical fungi, V1st
  • [5] TREATMENT OF INVASIVE ASPERGILLOSIS WITH ITRACONAZOLE
    DENNING, DW
    TUCKER, RM
    HANSON, LH
    STEVENS, DA
    [J]. AMERICAN JOURNAL OF MEDICINE, 1989, 86 (06) : 791 - 800
  • [6] INVITRO SUSCEPTIBILITY AND SYNERGY STUDIES OF ASPERGILLUS SPECIES TO CONVENTIONAL AND NEW AGENTS
    DENNING, DW
    HANSON, LH
    PERLMAN, AM
    STEVENS, DA
    [J]. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 1992, 15 (01) : 21 - 34
  • [7] NIAID MYCOSES STUDY-GROUP MULTICENTER TRIAL OF ORAL ITRACONAZOLE THERAPY FOR INVASIVE ASPERGILLOSIS
    DENNING, DW
    LEE, JY
    HOSTETLER, JS
    PAPPAS, P
    KAUFFMAN, CA
    DEWSNUP, DH
    GALGIANI, JN
    GRAYBILL, JR
    SUGAR, AM
    CATANZARO, A
    GALLIS, H
    PERFECT, JR
    DOCKERY, B
    DISMUKES, WE
    STEVENS, DA
    [J]. AMERICAN JOURNAL OF MEDICINE, 1994, 97 (02) : 135 - 144
  • [8] INVITRO ACTIVITY OF SAPERCONAZOLE (R66-905) COMPARED WITH AMPHOTERICIN-B AND ITRACONAZOLE AGAINST ASPERGILLUS SPECIES
    DENNING, DW
    HANSON, LH
    STEVENS, DA
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1990, 9 (09) : 693 - 697
  • [9] Therapeutic outcome in invasive aspergillosis
    Denning, DW
    [J]. CLINICAL INFECTIOUS DISEASES, 1996, 23 (03) : 608 - 615
  • [10] DENNING DW, 1990, REV INFECT DIS, V12, P1147